Treatment and prevention of liver adverse conditions using gallium
The invention provides methods and compositions for treating adverse conditions of the liver in an individual. A pharmaceutical composition including gallium, in the form of a coordination complex of gallium (III), a salt of gallium (III), an inorganic gallium (III) compound other than a gallium salt, or protein-bound gallium (III), together with a pharmaceutically acceptable carrier, is administered to the individual in an amount sufficient to provide a therapeutically or prophylactically effective serum gallium level.
1 . A method for treating an adverse condition of the liver in an individual in need thereof, comprising administering to the individual a unit dose of a gallium-containing composition, wherein said unit dose comprises an amount of said gallium-containing composition sufficient to provide a therapeutically effective serum gallium level.
2 . The method of claim 1 , wherein said therapeutically effective serum gallium level is at least about 10 ng/mL.
3 . The method of claim 1 , wherein said therapeutically effective serum gallium level is at least about 100 ng/mL.
4 . The method of claim 1 , wherein said therapeutically effective serum gallium level is at least about 500 ng/mL.
5 . The method of claim 1 , wherein said method comprises administering said gallium-containing composition to a human in an amount totaling about 2 mg/kg to about 550 mg/kg gallium per day.
6 . The method of claim 5 , wherein said gallium-containing composition is administered as a single dose per day.
7 . The method of claim 5 , wherein said gallium-containing composition is administered as multiple doses per day.
8 . The method of claim 1 , wherein said gallium-containing composition comprises a coordination complex of gallium(III), a salt of gallium (III), an inorganic compound of gallium (III), or protein-bound gallium (III).
9 . The method of claim 1 , wherein said gallium-containing composition comprises a coordination complex in the form of a neutral 3:1 (hydroxypyrone:gallium) complex in which each hydroxypyrone molecule is either unsubstituted or substituted with one, two, or three C 1 -C 6 alkyl substituents.
10 . The method of claim 9 , wherein each hydroxypyrone molecule is selected from the group consisting of 3-hydroxy-4-pyrone, 3-hydroxy-2-methyl-4-pyrone, 3-hydroxy-2-ethyl-4-pyrone, and 3-hydroxy-6-methyl-4-pyrone.
11 . The method of claim 10 , wherein each hydroxypyrone molecule is 3-hydroxy-2-methyl-4-pyrone.
12 . The method of claim 10 , wherein each hydroxypyrone molecule is 3-hydroxy-2-ethyl-4-pyrone.
13 . The method of claim 9 , wherein said gallium-containing composition is administered orally.
14 . The method of claim 1 , wherein said therapeutically effective serum level is achieved within about 1 hour to about 12 hours after administration of the unit dose.
15 . The method of claim 1 , wherein the adverse condition comprises hypertrophy of the liver.
16 . The method of claim 1 , wherein the adverse liver condition is caused by alcohol use, a hepatotoxic medication, radiation, exposure to a toxic substance, or traumatic injury to the liver.
17 . The method of claim 16 , wherein the adverse liver condition is caused by a hepatotoxic medication selected from the group consisting of anti-inflammatory agents, lipid-lowering agents, immunosuppressant agents, antidiabetic agents, antibiotics, antifingal agents, retinoids, anticonvulsant agents, psychotropic agents, and hormones, and combinations thereof.
18 . The method of claim 16 , wherein the adverse liver condition is caused by exposure to a toxic substance selected from the group consisting of an environmental pollutant, a halide-hydrocarbon, petroleum, a petroleum byproduct, a pesticide, a chemical compound used in manufacturing, an organic solvent, and a pyrrolizidine alkaloid.
19 . The method of claim 1 , wherein the adverse liver condition comprises a liver disease selected from steatosis, alcoholic liver disease, primary biliary cirrhosis, hemochromatosis, Wilson's disease, a cystic disease, an inflammatory liver disease, hepatitis, and primary sclerosing cholangitis.
20 . The method of claim 1 , wherein said gallium-containing composition is administered in combination with a second active agent indicated for treatment of the adverse liver condition.
21 . The method of claim 20 , wherein the adverse liver condition is hepatitis and the second active agent is an interferon, a nucleoside agent, or a combination thereof.
22 . A method for mitigating potential liver damage resulting from administration of a pharmacologically active agent to an individual, comprising administering a unit dose of a gallium-containing composition before, during, or subsequent to administration of the pharmacologically active agent to the individual, wherein said unit dose comprises an amount of said gallium-containing composition sufficient to provide a prophylactically effective serum gallium level.
23 . The method of claim 22 , wherein said prophylactically effective serum gallium level is at least about 10 ng/mL.
24 . The method of claim 22 , wherein said prophylactically effective serum gallium level is at least about 100 ng/mL.
25 . The method of claim 22 , wherein said prophylactically effective serum gallium level is at least about 500 ng/mL.
26 . The method of claim 22 , wherein the pharmacologically active agent and the gallium-containing composition are administered simultaneously.
27 . The method of claim 26 , wherein the pharmacologically active agent and the gallium-containing composition are administered in a single formulation.
28 . The method of claim 22 , wherein the pharmacologically active agent and the gallium-containing composition are administered sequentially.
29 . The method of claim 28 , wherein the pharmacologically active agent and the gallium-containing composition are administered within the context of different dosage regimens.
30 . The method of claim 22 , wherein the pharmacologically active agent is selected from the group consisting of anti-inflammatory agents, lipid-lowering agents, immunosuppressant agents, antidiabetic agents, antibiotics, antifungal agents, retinoids, anticonvulsant agents, psychotropic agents, hormones, and combinations thereof.
31 . A method for mitigating potential liver damage resulting from radiation therapy to an individual, comprising administering a unit dose of a gallium-containing composition before, during, or subsequent to administration of radiation therapy to the individual, wherein said unit dose comprises an amount of said gallium-containing composition sufficient to provide a prophylactically effective serum gallium level.
32 . The method of claim 31 , wherein said prophylactically effective serum gallium level is at least about 10 ng/mL.
33 . The method of claim 31 , wherein said prophylactically effective serum gallium level is at least about 100 ng/mL.
34 . The method of claim 31 , wherein said prophylactically effective serum gallium level is at least about 500 ng/mL.
35 . A method for mitigating potential liver damage resulting from exposure of an individual to a toxic substance, comprising administering a unit dose of a gallium-containing composition before, during, or subsequent to exposure of the individual to the toxic substance, wherein said unit dose comprises an amount of said gallium-containing composition sufficient to provide a prophylactically effective serum gallium level.
36 . The method of claim 35 , wherein said prophylactically effective serum gallium level is at least about 10 ng/mL.
37 . The method of claim 35 , wherein said prophylactically effective serum gallium level is at least about 100 ng/mL.
38 . The method of claim 35 , wherein said prophylactically effective serum gallium level is at least about 500 ng/mL.
39 . The method of claim 35 , wherein said toxic substance is selected from an environmental pollutant, a halide-hydrocarbon, petroleum, a petroleum byproduct, a pesticide, a chemical compound used in manufacturing, an organic solvent, and a pyrrolizidine alkaloid.
40 . A pharmaceutical composition for treatment or mitigation of an adverse condition of the liver, the composition comprising: (a) an amount of a gallium-containing composition sufficient to provide a therapeutically effective serum gallium level; and (b) a therapeutically effective amount of a second active agent indicated for treatment of the adverse condition.
41 . The pharmaceutical composition of claim 40 , wherein the therapeutically effective serum gallium level is at least about 10 ng/mL.
42 . The pharmaceutical composition of claim 40 , wherein the therapeutically effective serum gallium level is at least about 100 ng/mL.
43 . The pharmaceutical composition of claim 40 , wherein the therapeutically effective serum gallium level is at least about 500 ng/mL.
44 . The pharmaceutical composition of claim 40 , wherein the adverse liver condition is hepatitis and the second active agent is an interferon, a nucleoside agent, or a combination thereof.
45 . The pharmaceutical composition of claim 40 , wherein said gallium-containing composition comprises a coordination complex of gallium (III), a salt of gallium (III), an inorganic compound of gallium (III), or protein-bound gallium (III).
46 . The pharmaceutical composition of claim 40 , wherein said gallium-containing composition comprises a coordination complex in the form of a neutral 3:1 (hydroxypyrone:gallium) complex in which each hydroxypyrone molecule is either unsubstituted or substituted with one, two, or three C 1 -C 6 substituents.
47 . The pharmaceutical composition of claim 46 , wherein each hydroxypyrone molecule is selected from the group consisting of 3-hydroxy-4-pyrone, 3-hydroxy-2-methyl-4-pyrone, 3-hydroxy-2-ethyl-4-pyrone, and 3-hydroxy-6-methyl-4-pyrone.
48 . The pharmaceutical composition of claim 46 , wherein each hydroxypyrone molecule is 3-hydroxy-2-methyl-4-pyrone.
49 . The pharmaceutical composition of claim 46 , wherein each hydroxypyrone molecule is 3-hydroxy-2-ethyl-4-pyrone.
50 . The pharmaceutical composition of claim 40 , wherein the composition is formulated for parenteral administration.
51 . The pharmaceutical composition of claim 40 , wherein the composition is formulated for oral administration and the composition comprises an oral dosage form.
52 . The pharmaceutical composition of claim 50 , wherein the composition is formulated for transdermal or transmucosal administration.
53 . A transdermal delivery system comprising a drug reservoir comprising the composition of claim 42 .
54 . A kit for treatment or mitigation of an adverse condition of the liver comprising (a) at least one unit dose of a gallium-containing composition, wherein the unit dose comprises an amount of the gallium-containing composition sufficient to provide a therapeutically or prophylactically effective serum gallium level following administration of the composition to an individual; and (b) instructions for use of the gallium-containing composition to treat or mitigate the adverse condition of the liver.
55 . The kit of claim 54 , wherein the gallium-containing composition is formulated for oral administration and the unit dose is in the form of an oral dosage form.
56 . The kit of claim 55 , wherein the gallium-containing composition comprises a coordination complex in the form of a neutral 3:1 (hydroxypyrone:gallium) complex in which each hydroxypyrone molecule is either unsubstituted or substituted with one, two, or three C 1 -C 6 alkyl substituents.
57 . The kit of claim 56 , wherein each hydroxypyrone molecule is selected from the group consisting of 3-hydroxy-4-pyrone, 3-hydroxy-2-methyl-4-pyrone, 3-hydroxy-2-ethyl-4-pyrone, and 3-hydroxy-6-methyl-4-pyrone.
58 . The method of claim 57 , wherein each hydroxypyrone molecule is 3-hydroxy-2-methyl-4-pyrone.
59 . The method of claim 57 , wherein each hydroxypyrone molecule is 3-hydroxy-2-ethyl-4-pyrone.